Skip to main content
Premium Trial:

Request an Annual Quote

Cleveland HeartLab Acquires MIRISK Test

NEW YORK (GenomeWeb) – Cleveland HeartLab announced today it has acquired the MIRISK cardiovascular disease risk assessment tool for an undisclosed amount.

Aviir, which entered into bankruptcy in early 2014, previously owned MIRISK. The test was developed by researchers at Stanford University School of Medicine and uses a proprietary algorithm to analyze key proteins in blood associated with the development of vulnerable plaque. The use of MIRISK, when factoring in other risk factors, can determine an individual's risk of having a heart attack within a five-year period, CHL said.

CHL's acquisition includes intellectual property around the test, copyrights, and brand assets.

Studies have validated CHL's own proprietary cardiovascular disease inflammation test, and MIRISK "complements our arsenal of prognostic testing," Marc Penn, director of research at Summa Cardiovascular Institute and CMO at CHL, said in a statement. "Together, these two represent a significant leap forward in the advancement of [cardiovascular disease] risk assessment, and, ultimately, heart attack and stroke prevention."

About 600,000 Americans die each year from cardiovascular disease, CHL said, citing statistics from the US Centers for Disease Control and Prevention.